Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways
Abstract The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value‐based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.3193 |
| _version_ | 1818513703335624704 |
|---|---|
| author | J. Russell Hoverman |
| author_facet | J. Russell Hoverman |
| author_sort | J. Russell Hoverman |
| collection | DOAJ |
| description | Abstract The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value‐based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology drug research and its relationship to value‐based cancer care. Clinical Chemotherapy Pathways are proposed as a unifying structure to bring together disparate sources of data to increase value. |
| first_indexed | 2024-12-11T00:05:16Z |
| format | Article |
| id | doaj.art-86ee1c5247a1404ead0c79ee55ef55e7 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-11T00:05:16Z |
| publishDate | 2020-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-86ee1c5247a1404ead0c79ee55ef55e72022-12-22T01:28:21ZengWileyCancer Medicine2045-76342020-08-019155306531110.1002/cam4.3193Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathwaysJ. Russell Hoverman0Value‐based Programs US Oncology/McKesson Specialty Health Texas Oncology Dallas TX USAAbstract The United States spends nearly 1/5th of its GDP on healthcare. Yet, to achieve value‐based care, the Economist describes the US healthcare system as handicapped by multiple, disparate silos that prevent the organization and sharing of data. This paper explores the current state of clinical oncology drug research and its relationship to value‐based cancer care. Clinical Chemotherapy Pathways are proposed as a unifying structure to bring together disparate sources of data to increase value.https://doi.org/10.1002/cam4.3193cancer managementchemotherapyclinical cancer researchmedical oncology |
| spellingShingle | J. Russell Hoverman Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways Cancer Medicine cancer management chemotherapy clinical cancer research medical oncology |
| title | Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways |
| title_full | Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways |
| title_fullStr | Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways |
| title_full_unstemmed | Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways |
| title_short | Rethinking clinical oncology drug research in an era of value‐based cancer care: A role for chemotherapy pathways |
| title_sort | rethinking clinical oncology drug research in an era of value based cancer care a role for chemotherapy pathways |
| topic | cancer management chemotherapy clinical cancer research medical oncology |
| url | https://doi.org/10.1002/cam4.3193 |
| work_keys_str_mv | AT jrussellhoverman rethinkingclinicaloncologydrugresearchinaneraofvaluebasedcancercarearoleforchemotherapypathways |